Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Orbimed Downgrades its Position in Intercept Pharmaceuticals

Orbimed Advisors, Intercept Pharmaceuticals: In a recent SEC filing, Samuel Isaly and his hedge fund, Orbimed Advisors, reported decreasing their holding in Intercept Pharmaceuticals Inc (NASDAQ:ICPT) to 9.22% of its outstanding shares. Orbimed now owns around 1.78 million shares of Intercept, with an aggregate value of $106.34 million, at the current stock price of the company. In its latest 13F, Orbimed reported 2.15 million shares of the company.

Intercept Pharmaceuticals Inc (NASDAQ:ICPT)

Disclosure: none

Recommended Reading:

Wexford Makes Two Thursday Afternoon Moves: Revett & Arno Therapeutics

Steven Cohen May Sell Stock in Company Whose Founder Went to Prison For Insider Trading

Gabelli Also Selling Some Strattec Security Shares